From: Lack of association between polymorphisms of MASP2and susceptibility to SARS coronavirus infection
 | SARS cases | controls |  |  |  | ||
---|---|---|---|---|---|---|---|
Genotype | P1 | P2 | C1 | C2 | P1 vs.P2 | C1vs.C2 | P1, P2 vs. C1, C2 |
 | (n = 272) | (n = 104) | (n = 232) | (n = 291) | P | P | P |
rs2261695 | Â | Â | Â | Â | Â | Â | Â |
AA | 189 (70.3%) | 73 (75.3%) | 174 (75.0%) | 193 (70.4%) | 0.35 | 0.25 | 0.76 |
AG | 77 (28.6%) | 22 (22.7%) | 56 (24.1%) | 78 (28.5%) | Â | Â | Â |
GG | 3 (1.1%) | 2 (2.0%) | 2 (0.9%) | 3 (1.1%) | Â | Â | Â |
rs2273346 | Â | Â | Â | Â | Â | Â | Â |
TT | 186 (68.4%) | 64 (61.5%) | 147 (63.4%) | 190 (66.2%) | 0.21 | 0.50 | 0.63 |
TC | 78 (28.7%) | 36 (34.6%) | 71 (30.6%) | 82 (28.6%) | Â | Â | Â |
CC | 8 (2.9%) | 4 (3.8%) | 14 (6%) | 15 (5.2%) | Â | Â | Â |
rs12711521 | Â | Â | Â | Â | Â | Â | Â |
TT | 105 (38.5%) | 58 (55.8%) | 106 (45.7%) | 139 (47.8%) | 0.003 | 0.64 | 0.30 |
TG | 137 (50.5%) | 36 (34.6%) | 95 (40.9%) | 108 (37.1%) | Â | Â | Â |
GG | 30 (11.0%) | 10 (9.6%) | 31 (13.4%) | 44 (15.1%) | Â | Â | Â |
rs7548659 | Â | Â | Â | Â | Â | Â | Â |
TT | 173 (69.5%) | 70 (67.3%) | 157 (67.7%) | 205 (70.5%) | 0.69 | 0.50 | 0.91 |
TG | 61 (24.5%) | 25 (24.0%) | 67 (28.9%) | 75 (27.8%) | Â | Â | Â |
GG | 15 (6.0%) | 9 (8.7%) | 8 (3.4%) | 11 (1.7%) | Â | Â | Â |
Diplotypea | Â | Â | Â | Â | Â | Â | Â |
TT | 344 (63.2%) | 128 (61.5%) | 304 (65.5%) | 380 (65.3%) | 0.89 | 1.00 | 0.31 |
TG | 108 (19.9%) | 42 (20.2%) | 60 (12.9%) | 76 (13.0%) | Â | Â | Â |
CT | 6 (1.1%) | 4 (1.9%) | 2 (0.5%) | 4 (0.7%) | Â | Â | Â |
CG | 86 (15.8%) | 34 (16.4%) | 98 (21.1%) | 122 (21.0%) | Â | Â | Â |